Gilead Increases Investment In Arcus; Firms Abandon Chemo-Free Combo Study
With a $320m equity investment, Gilead will now own 33% of partner Arcus, which it said reinforces its optimism around the anti-TIGIT class for oncology.
With a $320m equity investment, Gilead will now own 33% of partner Arcus, which it said reinforces its optimism around the anti-TIGIT class for oncology.